CJC-1295 success rate: what the evidence actually shows

Last updated 2026-07-30

Is there an actual published success rate for CJC-1295?

No. Search PubMed or ClinicalTrials.gov and you won't find a trial that reports "X% of subjects succeeded on CJC-1295." That framing doesn't exist in the literature because growth hormone secretagogue studies measure continuous outcomes, not pass/fail ones: GH pulse amplitude, area under the curve, IGF-1 concentration change, half-life. Success rate is a marketing-friendly phrase that got imported from bodybuilding forums, not a clinical endpoint. What the science does show is response rate in a narrower sense: the proportion of subjects whose GH or IGF-1 levels rose measurably after dosing. In the foundational human study of modified GRF(1-29) with drug affinity complex (the compound that became known as CJC-1295), a single injection produced sustained GH elevation for six or more days, and repeated dosing over weeks raised IGF-1 levels in a dose-dependent way across all dose groups tested ^[1]. That's about as close to a "success rate" as the data gets, and it's a pharmacodynamic one, not a physique or symptom outcome. If you're comparing anecdotal reports to trial data, it helps to read them side by side. Our CJC-1295 reviews page collects user-reported experiences and flags where they diverge from what's actually been measured in a lab.

What did the original CJC-1295 clinical trial actually measure?

The 2006 study by Teichman and colleagues, published in the Journal of Clinical Endocrinology & Metabolism, is the trial almost everyone cites when they talk about CJC-1295 evidence. It tested modified GRF(1-29) with DAC in healthy men and women, using single and multiple-dose designs. Key findings: a single subcutaneous injection raised mean plasma GH within 30 minutes and kept it elevated above baseline for about six days at the higher doses tested, with an apparent half-life the authors described as roughly 6 to 8 days depending on dose ^[1]. With multiple doses given every 7 to 14 days over several weeks, mean IGF-1 levels rose and stayed elevated, with the higher-dose groups showing increases the authors called sustained "without evidence of desensitization" over the study period ^[1]. That's a genuinely useful finding. It means the DAC modification does what it was designed to do, extend the drug's action so you don't need daily injections to keep GH pulsing. But the study had a small sample, was industry-sponsored (the compound was developed by Ipsen and ConjuChem), and did not run long enough to assess things like body composition, strength, or long-term safety at the doses researchers actually use recreationally. Nobody has replicated it independently at scale in the nearly two decades since.

CJC-1295 with DAC vs without DAC: does the success rate differ?

This is the single most confused point in CJC-1295 discussion, and it matters because the two versions behave completely differently in the body. CJC-1295 with DAC is the molecule from the Teichman trial: modified GRF(1-29) bound to a drug affinity complex that binds serum albumin, extending its half-life to multiple days ^[1]. Dosing is infrequent, often described as one to two times a week in practitioner protocols, because the drug lingers. CJC-1295 without DAC (often sold or discussed as "Mod GRF 1-29") is the same core peptide sequence minus the albumin-binding tail. Its half-life is short, on the order of minutes, closer to native GHRH. This version needs multiple daily injections to produce a GH pulse pattern that mimics natural release, which is exactly why people pair it tightly with a GHRP like ipamorelin timed around meals and sleep. Here's the practical confusion: most of the "CJC-1295 works great" anecdotes online don't specify which version the person used, and a lot of gray-market vendors mislabel or blend the two. If someone reports fast results from "CJC-1295," ask which version. A no-DAC user dosing three times daily is running a fundamentally different pharmacokinetic profile than a DAC user injecting twice a week, and their sense of what counts as a good response will differ too. | Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |

Why does CJC-1295 get paired with ipamorelin, and does that combination have better evidence?

The rationale is mechanistic, not a proven combined-effect claim backed by human outcome trials specifically testing the pairing. CJC-1295 is a GHRH analogue: it acts on the GHRH receptor in the pituitary to promote GH synthesis and release. Ipamorelin is a ghrelin-receptor agonist (a GHRP): it acts on a separate receptor pathway and also suppresses somatostatin, the hormone that normally puts the brakes on GH release. GHRH research going back decades shows that combining a GHRH analogue with a GH-releasing peptide produces a larger acute GH pulse than either compound alone, because they hit two different, complementary points in the regulatory pathway ^[2]. That two-receptor logic is well established for GHRH and GHRP classes generally. What's genuinely not established is a dedicated randomized trial of CJC-1295 specifically plus ipamorelin specifically, measuring hard outcomes like lean mass, strength, or fat loss over months in the population actually using it. The combination's popularity comes from extrapolating known GHRH/GHRP interaction plus practitioner and forum experience, not from a study that enrolled people, ran the stack, and reported results against a placebo arm. If you're deciding whether the stack is worth the added cost and complexity over CJC-1295 alone, our CJC-1295 pros and cons piece breaks down that tradeoff directly.

What outcomes have actually been measured in GHRH analogue research, and how strong is that evidence?

Beyond the CJC-1295-specific trial, there's a broader base of research on GHRH analogues and GH secretagogues generally that's worth separating from CJC-1295-branded anecdote. Tesamorelin, a different GHRH analogue, has FDA approval for reducing excess abdominal fat in HIV-associated lipodystrophy, based on randomized, placebo-controlled trials showing measurable visceral fat reduction over 26 weeks ^[3]. That's a real, approved outcome, but it's tesamorelin, a distinct molecule, in a specific patient population, not general CJC-1295 use in healthy adults. Sermorelin, an earlier GHRH(1-29) analogue, has decades of use in diagnosing GH deficiency and some pediatric growth trials, giving researchers a longer track record for that GHRH fragment's basic safety profile, though again in different contexts (short-term diagnostic use, or pediatric growth deficiency) than long-term adult self-administration ^[4]. The honest summary: the GHRH mechanism itself is well studied and understood. CJC-1295 specifically has one solid human PK/PD trial from 2006 ^[1], a handful of smaller or animal studies, and a mountain of user reports that were never designed to be evidence. If someone tells you CJC-1295 has a "90% success rate," ask them to point to the study. There isn't one.

How is 'success' even defined by people using CJC-1295?

This is worth sitting with because it explains why success rate as a question doesn't have a clean answer. Ask ten people what a successful CJC-1295 experience looks like and you'll get different definitions. Some people mean subjective sleep quality, since GH release is tied to slow-wave sleep and many users report feeling like they sleep deeper within the first couple weeks. Some mean visible body composition change, fat loss around the midsection or a firmer look, which if it happens at all typically shows up over 8 to 12 weeks, not days. Some mean lab-measured IGF-1 change, which is the only one of these three that has direct trial support from the 2006 study ^[1]. Some mean joint comfort or recovery from training, which is almost entirely anecdotal territory with no controlled trial behind it for this specific compound. Because these are such different outcomes with such different timelines and evidence quality, lumping them into one success rate number would be dishonest even if someone tried to calculate it. For a realistic sense of what changes when, in what order, our CJC-1295 first month what to expect guide separates the early subjective effects from the slower measurable ones.

How much does dose affect whether CJC-1295 'works'?

Dose is the biggest lever in the actual trial data, more than almost anything discussed in forums. The Teichman study tested multiple dose levels and found a clear dose-response relationship: higher doses of modified GRF(1-29)/DAC produced larger and more sustained IGF-1 increases than lower doses, and the effect held up across repeated dosing cycles without the blunting (desensitization) some researchers worried about with continuous GHRH stimulation ^[1]. That matters for two reasons. First, it means underdosing is a real, quantifiable way to get a poor result, more than a bodybuilding-forum talking point. Second, it means dose-finding in real-world use is happening without the kind of dose-ranging safety data that exists for approved drugs like testosterone or tesamorelin, where the FDA-reviewed dose (tesamorelin at 2 mg daily, for example, in its approved indication) came out of formal trials ^[3]. With CJC-1295, people are often working from practitioner protocols, compounding pharmacy guidance, or forum consensus rather than an approved label. This is also where sourcing quality becomes inseparable from "success." A peptide vial that's underdosed, degraded, or mislabeled will never produce the response seen in the trial, no matter how well the injection schedule is followed. That's a sourcing and quality-control problem, not a mechanism problem, and it's one of the biggest reasons real-world results vary so much more than the trial data would predict.

Does age or baseline GH level change the odds of a good response?

Likely yes, based on general GH physiology, though CJC-1295 hasn't been tested across age brackets specifically. GH secretion naturally declines with age, a well-documented pattern sometimes called somatopause, and baseline pituitary GH reserve varies a lot between individuals even at the same age ^[4]. The practical implication, extrapolated from broader secretagogue research rather than a CJC-1295-specific trial: someone with lower baseline GH output (common in older adults, or in anyone with reduced pituitary reserve) may show a proportionally larger relative jump in GH/IGF-1 after stimulation, while someone already near their natural peak output has less room to climb. This is inference from the general GHRH/somatopause literature, not a finding reported in the CJC-1295 trial itself, and it should be labeled as such whenever it comes up. What this means practically: two people on an identical protocol can have very different subjective and lab outcomes, and neither one is necessarily doing anything wrong. Age, baseline hormone status, sleep quality, training load, and diet all shift where someone lands, which again is exactly why a single success rate percentage would flatten a lot of real variation.

What does 'failure' usually look like when CJC-1295 doesn't work?

In practice, reported non-response tends to cluster around a few identifiable causes rather than random bad luck. The most common one is product quality. Peptides are fragile, sensitive to heat, light, and improper reconstitution, and gray-market supply chains have no FDA oversight verifying purity or concentration. A vial that's degraded or underdosed will predictably underperform, and there's no way for a buyer to know without third-party testing. The second common one is dosing or timing mismatched to the DAC/no-DAC distinction covered earlier: someone using the long-acting DAC version but injecting it like the short-acting version (or vice versa) is working against the pharmacokinetics rather than with them. The third is unrealistic timeline expectations. Because IGF-1 changes accumulate over weeks in the trial data ^[1], not days, people who judge the compound after a week or two are often judging it before it had a chance to do what the pharmacology says it does. And the fourth, less discussed, is that some people simply may not be meaningfully GH-deficient to begin with, so a healthy 30-year-old with normal GH output has a different response ceiling than someone whose baseline secretion is already suppressed. If you're weighing whether to start at all given these variables, is CJC-1295 worth it walks through the cost, time, and realistic-expectation math in more depth.

What do before-and-after reports actually show, and how should you read them?

Before-and-after posts are the most visible form of "evidence" for CJC-1295 online, and they're also the least controlled. There's no blinding, no placebo comparison, and almost never any accompanying lab work showing IGF-1 or GH change alongside the photo. That doesn't make them worthless. It makes them a different category of information than a clinical trial. A consistent pattern across many independent, unconnected reports (better sleep in weeks 1 to 3, slower body composition shifts over months) is at least directionally consistent with what the GHRH mechanism and the 2006 trial's IGF-1 timeline would predict ^[1]. What before-and-afters can't tell you is how much of a given result came from the peptide itself versus concurrent diet changes, training changes, or other compounds stacked alongside it, which is extremely common in these reports and rarely disclosed clearly. Our CJC-1295 before and after page collects these reports and is explicit about that limitation rather than presenting them as trial-grade proof.

Is CJC-1295 legal to buy, and does that affect quality and outcomes?

In the United States, CJC-1295 is not FDA-approved for human use and is not legally marketed as a drug or dietary supplement for that purpose. The FDA has published guidance identifying certain bulk peptides, including some GH secretagogues, as inappropriate for compounding because of safety and effectiveness concerns not yet resolved, meaning it exists in a gray zone: sold by research chemical suppliers "for research use only," while widely purchased for personal use anyway ^[5]. This regulatory gap directly connects to the success-rate question. Because CJC-1295 isn't an approved drug, there's no FDA-mandated manufacturing standard, no required purity testing, and no enforcement against mislabeling the way there is for prescription pharmaceuticals. That's a major reason outcomes vary so widely across sources, and it's a bigger driver of inconsistent results than almost anything about the molecule's biology. The more defensible path, if someone decides to pursue this, is working through a provider who reviews the protocol and sources through a licensed compounding pharmacy rather than an unregulated research-chemical seller. CJC-1295 Co's provider-reviewed listings connect readers to that kind of pathway and name the fulfilling pharmacy partner rather than shipping product directly, which at minimum puts a licensed pharmacist and clinician between the reader and the vial.

So what's the honest bottom line on CJC-1295's success rate?

There's no clean number to give you, and anyone who gives you one is guessing or selling something. What the actual evidence supports: a single well-designed 2006 trial showing modified GRF(1-29)/DAC reliably raises GH acutely and IGF-1 over weeks, in a dose-dependent way, in the healthy adults it tested ^[1]. What the evidence does not support: a percentage chance of subjective success, a guaranteed body composition outcome, or proof that the CJC-1295/ipamorelin combination outperforms CJC-1295 alone in a controlled human trial. The mechanistic case for the combination is sound; the outcome data specific to that pairing isn't there yet ^[2]. If you're going to try it, treat the DAC/no-DAC distinction as the first decision, treat dose and sourcing as the biggest variables you actually control, and treat the multi-week IGF-1 timeline from the trial data as your realistic benchmark rather than a two-week forum post.

Frequently asked questions

What percentage of people see results from CJC-1295?

No published study reports a percentage success rate for CJC-1295 in humans. The one major human trial (Teichman et al., 2006) measured continuous outcomes like GH and IGF-1 levels, not a pass/fail success rate, and found dose-dependent increases across all dose groups tested rather than a binary responder/non-responder split.

How long does it take to know if CJC-1295 is working?

Based on trial data, GH rises within 30 minutes of a dose, but IGF-1, the more meaningful longer-term marker, builds over repeated dosing across several weeks. Practically, most people shouldn't expect to judge results before 6 to 8 weeks of consistent use, and body composition changes typically take longer than that.

Is CJC-1295 with DAC more effective than without DAC?

They're not directly comparable as "more or less effective," they have different pharmacokinetics. With DAC has a multi-day half-life and needs infrequent dosing; without DAC clears in minutes and needs multiple daily injections to approximate a natural pulsatile GH pattern. Neither has been shown in trials to be categorically superior for outcomes; they're different tools with different schedules.

Does CJC-1295 work better with ipamorelin than alone?

The mechanistic rationale is solid: they act on different receptors (GHRH receptor versus ghrelin receptor) and GHRH/GHRP combinations are known to produce larger acute GH pulses than either class alone. But no dedicated randomized trial has tested CJC-1295 plus ipamorelin against CJC-1295 alone for outcomes like body composition, so the added benefit is plausible, not proven.

Why do some people say CJC-1295 didn't work for them?

Common causes reported anecdotally include poor product quality from unregulated sourcing, dosing or timing mismatched to the DAC/no-DAC version being used, judging results too early relative to the multi-week IGF-1 timeline seen in trial data, and individual variation in baseline GH output that limits how much room there is to respond.

Is there a clinical trial specifically on CJC-1295 and body composition?

Not a large-scale one. The 2006 Teichman study focused on GH and IGF-1 pharmacokinetics and pharmacodynamics, not body composition, strength, or fat mass endpoints. Body composition claims circulating online come from user reports and extrapolation from GH physiology generally, not a dedicated CJC-1295 body composition trial.

Is CJC-1295 FDA-approved?

No. CJC-1295 has no FDA approval for any human indication. It falls into a regulatory gray area often sold as a research chemical, and the FDA has flagged certain bulk peptide substances used in compounding, including GH secretagogues, over unresolved safety and effectiveness concerns.

How does CJC-1295 compare to tesamorelin, which is FDA-approved?

Tesamorelin is a different GHRH analogue, FDA-approved specifically for reducing excess visceral fat in HIV-associated lipodystrophy based on placebo-controlled trials. CJC-1295 has no equivalent approval or outcome-based trial; its evidence base is limited to the GH/IGF-1 pharmacokinetic study, so the two shouldn't be treated as interchangeable in terms of evidence strength.

Does age affect how well CJC-1295 works?

Likely, based on general GH physiology rather than CJC-1295-specific trials. GH output naturally declines with age (somatopause), so people with lower baseline GH may see a larger relative response to stimulation, while those near natural peak output have less room to climb. This is inference from broader GH research, not a finding from the CJC-1295 trial itself.

What's the difference between anecdotal reports and clinical evidence for CJC-1295?

Anecdotal reports (forum posts, before-and-after photos) lack blinding, placebo comparison, and lab confirmation, and often involve concurrent diet, training, or other compound changes that aren't disclosed. Clinical evidence, limited here to one 2006 human PK/PD trial, uses controlled dosing and measured GH/IGF-1 levels, but hasn't tested body composition or long-term outcomes.

Can product quality affect whether CJC-1295 produces results?

Yes, significantly. Because CJC-1295 isn't FDA-regulated as a drug, there's no mandated purity or potency testing for the research-chemical suppliers many people buy from. Degraded, underdosed, or mislabeled product is a commonly cited reason for poor results, independent of the compound's actual pharmacology.

Should I get CJC-1295 through a provider instead of a research chemical site?

Working through a provider who reviews the protocol and routes sourcing through a licensed compounding pharmacy adds a layer of clinical oversight and quality control that unregulated research-chemical sellers don't offer. It doesn't create clinical trial-level evidence, but it addresses the sourcing-quality variable that drives a lot of inconsistent real-world outcomes.

Sources

1. Teichman SL et al., Journal of Clinical Endocrinology & Metabolism, 2006: Single and multiple-dose human trial of modified GRF(1-29)/DAC showing sustained GH elevation and dose-dependent IGF-1 increases without desensitization
2. NCBI Bookshelf, Endotext (Growth Hormone Releasing Hormone and Analogs chapter): GHRH analogues and GH-releasing peptides act via distinct receptor pathways and combined administration produces larger acute GH pulses than either alone
3. FDA, Egrifta (tesamorelin) prescribing information: Tesamorelin is FDA-approved specifically for reduction of excess abdominal fat in HIV-associated lipodystrophy based on placebo-controlled trials
4. NIH National Institute on Aging, Growth hormone research background: Growth hormone secretion declines with age, a pattern relevant to baseline GH reserve and secretagogue response
5. FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A: FDA guidance on bulk substances nominated for compounding, relevant to the regulatory status of peptides like CJC-1295